Background: In heart failure with reduced left ventricular ejection fraction (HFrEF) patients the effects of exercisebased cardiac rehabilitation on top of state-of-the-art pharmacological and device therapy on mortality, hospitalization, exercise capacity and quality-of-life are not well established. Design: The design of this study involved a structured review and meta-analysis. Methods: Evaluation of randomised controlled trials of exercise-based cardiac rehabilitation in HFrEF-patients with left ventricular ejection fraction 40% of any aetiology with a follow-up of !6 months published in 1999 or later. Results: Out of 12,229 abstracts, 25 randomised controlled trials including 4481 HFrEF-patients were included in the final evaluation. Heterogeneity in study population, study design and exercise-based cardiac rehabilitation-intervention was evident. No significant difference in the effect of exercise-based cardiac rehabilitation on mortality compared to control-group was found (hazard ratio 0.75, 95% confidence interval 0.39-1.41, four studies; 12-months follow-up: relative risk 1.29, 95% confidence interval 0.66-2.49, eight studies; six-months follow-up: relative risk 0.91, 95% confidence interval 0.26-3.16, seven studies). In addition there was no significant difference between the groups with respect to 'hospitalization-for-any-reason' (12-months follow-up: relative risk 0.79, 95% confidence interval 0.41-1.53, four studies), or 'hospitalization-due-to-heart-failure' (12-months follow-up: relative risk 0.59, 95% confidence interval 0.12-2.91, four studies; six-months follow-up: relative risk 0.84, 95% confidence interval 0.07-9.71, three studies). All studies show improvement of exercise capacity. Participation in exercise-based cardiac rehabilitation significantly improved quality-of-life as evaluated with the Kansas City Cardiomyopathy Questionnaire: (six-months follow-up: mean difference 1.94, 95% confidence interval 0.35-3.56, two studies), but no significant results emerged for qualityof-life measured by the Minnesota Living with Heart Failure Questionnaire (nine-months or more follow-up: mean difference -4.19, 95% confidence interval -10.51-2.12, seven studies; six-months follow-up: mean difference -5.97, 95% confidence interval -16.17-4.23, four studies).
Introduction
Chronic heart failure with reduced left ventricular ejection fraction (HFrEF) remains a major health problem with increasing prevalence. 1, 2 Within the next 25 years, an increase in heart-failure-related hospital admissions by 50% is expected, mainly due to the aging population. 3 Today, a broad spectrum of therapeutic options is available for HFrEF patients including state-of-the-art medications, device therapy (e.g. implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT)), interventional or surgical repair of mitral valve regurgitation and, finally, implantation of ventricular assist devices or heart transplantation. 1, 2 In spite of the therapeutic progress, the prognosis of HFrEF patients remains poor. 4 During an average follow-up of 47 months, a mortality of 32% has been reported in patients with left ventricular ejection fraction (LV-EF) of 35-50%, increasing to 41% in patients with LV-EF below 35%. 5 In addition, HFrEF is characterised by significant exercise intolerance caused primarily by skeletal muscle atrophy and dysfunction, which limits daily living activities and reduces health-related quality of life (QoL). 1, 2, 6 Moreover, the prevalence of frailty in HFrEF patients is high (15-74%) and known to be associated with disability, poor QoL, and outcome and/or higher hospital admittance rates. 7 Following proof-of-concept studies by Coats et al. 8 and Hambrecht et al. 9 which documented the efficacy and safety, respectively, of exercised-based cardiac rehabilitation (ebCR), multiple studies documented its potential to improve functional capacity, QoL and prognosis in patients with heart failure. [10] [11] [12] [13] [14] [15] [16] [17] In these studies, however, the populations under investigation were heterogeneous with respect to LV-EF (<35% up to >50%), New York Heart Association (NYHA) classification, and follow-up period. However, the effect of ebCR on morbidity and mortality on top of evidence-based state-of-the-art pharmaco-and device-therapy in high-risk patients with moderately to severely reduced LV-EF is not yet fully established. [10] [11] [12] [13] [14] [15] [16] [17] Although current guidelines recommend ebCR as an effective and safe therapeutic intervention, 1, 2, 6 HFrEF patients are still clearly underrepresented in CR settings worldwide.
Hence, the aim of this systematic review and metaanalysis was to evaluate whether or not ebCR is effective in reducing all-cause-mortality and hospitalization and improving exercise capacity (peak oxygen uptake (VO 2peak )) and QoL in HFrEF-patients with reduced LV-EF 40% on guideline-recommended pharmacoand device-therapy.
Methods
This systematic review was conducted and reported according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA). 18 The study protocol has been published previously in PROSPERO (CRD42017054833).
Study eligibility criteria
The study selection criteria (population, intervention, control, outcomes, and study designs) are outlined in detail in Table 1 .
To ascertain guideline-recommended heart failure treatment (e.g. medical treatment including beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, aldosterone receptor blockers, and devices (ICD, CRT, etc.)) only studies published in 1999 or later were included in this systematic review.
All-cause-mortality was defined as the primary endpoint. Predefined secondary endpoints were cardiovascular mortality, hospitalizations, cardiopulmonary exercise capacity and QoL, as outlined in Table 1 .
Data sources, search strategies and identification of studies 
Population:
Age: !18 years. Origin and presentation heart failure: patients with chronic heart failure of any aetiology with either reduced left ventricular ejection fraction (HFrEF; left ventricular ejection fraction (LVEF) 40% or preserved left ventricular ejection fraction (HFpEF). Baseline therapeutic requirements: included studies must have been performed during the era of chronic heart failure treatment including at least beta-blockers in combination with either angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) and/or aldosterone antagonist. Patients must not have previously received exercise-based cardiac rehabilitation. Intervention:
(a) Any form of structured and supervised exercise intervention (i.e. aerobic exercise training or resistance training or enduranceresistance training) alone or in combination with a comprehensive rehabilitation intervention (e.g. including information, education, motivation, psychological interventions etc.). The follow-up period must be six months or longer after randomization. Accepted study designs: was evaluated independently by the two reviewers according to a predefined scheme. The result of this primary selection was forwarded to the Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF) steering committee (BR, SG, MH, KJ) for internal control. Full text articles were assessed for final decision of eligibility. Studies were finally selected based on a consensus between the two expert reviewers and the steering committee (RN, BBW, BR, SG, MH, KJ). In case of disagreement, the decision of the majority was approved.
Study evaluation and risk of bias assessment
The literature search yielded no controlled cohort study that fulfilled the study selection criteria. Hence, this systematic review and meta-analysis includes randomised controlled trials (RCTs) only (Figure 1 ). The risk of bias was measured using the Cochrane Collaboration's tool for assessing risk of bias. 19 Additionally, imbalances regarding the baseline characteristics of the study groups were evaluated as a further criterion for assessing the risk of bias. 20 
Data extraction
A standardised data extraction form was used to individually extract data from full-text copies of included trials by two biometricians (MH, KJ). The following data were extracted: name of first author, year of publication, study location (country), study design; population: data sources, sample size, index events, other inclusion criteria and characteristics, inclusion period, mean age and gender proportion; intervention: number of participants; type of intervention (exercise only CR (CR-ex) or multikomponent CR (CR-mult) and aerobic intervention or aerobic plus resistance intervention); duration of single exercise and/or total number or CR sessions, number of CR exercise sessions per week, exercise mode and CR setting. Control: number of participants, treatment; outcome: follow-up-period, outcomes according to the CROS-HF protocol, instruments of measurement for QoL; overall results with respect to CROS-HFprotocol endpoints (Table 2) . 9, The primary reasons for study exclusion at the PICO selection level are given in Supplementary Material Table SM2 .
Statistical methods
The primary meta-analysis included all studies comparing ebCR with control groups. Where possible a subgroup analysis was performed comparing different types of intervention during CR (e.g. CR-ex vs CR-mult, aerobic exercise alone vs aerobic plus resistance exercise). The hazard ratio (HR) and its 95% confidence interval (CI) was used as an effect measure for Titles identified from electronic bibliographies and screened for retrieval n = 12229 Excluded n = 12125
Potentially appropriate full publications retrieved for full evaluation n = 104 Excluded inappropriate population n = 24 inappropriate study protocol n = 35 inappropriate outcome n = 15 inappropriate intervention n = 1 (total 75) Total RCTs included in meta-analysis n = 26 (29 publications) Figure 1 . A summary of study inclusion/exclusion process. 4 European Journal of Preventive Cardiology 0(00) time-to-event data. If HRs and associated variances could not be extracted directly from the trial publications, the data were obtained indirectly using methods as described by Parmar et al. 48 and Tierney et al. 49 For event data, the relative risk (RR) with its 95% CI was chosen as an effect measure. Ratios were defined as the effect in the ebCR group divided by the effect in the control group. For continuous outcomes, the mean difference (MD) of the final values with corresponding 95% CI was used. All MDs were calculated by subtracting the mean values of the control from the mean values of the ebCR group. Some publications only provided medians and interquartile ranges (IQRs) instead of means and standard deviations (SDs). In these cases mean and SD were estimated by methods proposed by Wan et al. 50 Random-effects meta-analyses were used to calculate overall effect estimates and CIs, as heterogeneity between the 'true' effects of the various ebCR programmes being evaluated was assumed. As a randomeffects model, the 'Knapp-Hartung approach' was applied. 51 Due to the high number of studies with no predefined event occurring during follow-up, the betabinomial model 52 was applied to estimate an overall effect for the event data. Only to visualise the study specific RR in the forest plots and to evaluate the statistical heterogeneity, a continuity correction of 0.5 was applied to studies without events.
Statistical heterogeneity of the results was checked by I 2 statistics 19 with 50-75% representing substantial and 75-100% considerable heterogeneity. A potential publication bias was evaluated by visual examination of funnel plot asymmetry for the primary outcome. As sensitivity analysis, a fixed-effect model for the primary endpoint was applied. To evaluate the influence of the HF-ACTION trial, a further sensitivity analysis was conducted by excluding the results of the HF-ACTION trial. Due to insufficient data, no further subgroup analyses were conducted. R version 3.4.4 (R Foundation for Statistical Computing, 2018) and the R meta package version 4.9-1 (developed by Guido Schwarzer) were used for statistical analyses.
Results

Study characteristics
Literature search yielded a total of 12,229 titles. Following the review of titles and abstracts, 104 publications remained for full text evaluation. Finally, 26 RCTs (29 publications) fulfilled all inclusion criteria of the CROS-HF-study and, therefore, were selected for the final review (Figure 1 ).
Within these finally selected RCTs, one pilot study including heart failure patients with preserved ejection fraction (HFpEF) was excluded 47 (Table 2) . Therefore, this review focusses on studies evaluating HF-patients with reduced ejection fraction (25 studies; 4481 patients, LV-EF 40%). Out of these 25 studies, seven studies (2759 patients) 22, 25, 27, 34, 37, 44, 45 included patients with LV-EF<35% only. The majority of the included studies represent single-centre studies (21 studies). The number of participants in most studies was small (25-216 participants) being dominated by one large randomised controlled study (HF-ACTION 2009). HF-ACTION contributed to 52% of all included patients. 37, 38 The follow-up periods varied widely from six months up to 10 years.
Four studies provided CR-mult and 21 studies applied CR-ex. All studies evaluated continuous aerobic exercise training. In 10 studies, continuous training was combined with resistance exercise. 24, [26] [27] [28] 31, 35, 36, 39, 41, 42 Two studies evaluated two intervention groups with different exercise modalities. 30, 45 In the CROS-HF evaluation, the two intervention-groups of Klocek et al. 40 were analysed together. In Ellingsen et al., 45 the results from the high intensity interval training (HIIT) group were not included in the analysis because this training modality was significantly different from that used in all other studies.
The dose of exercise training ranged widely across the studies under investigation with single session durations of 30-105 min, session frequencies of 2-7 sessions per week, and total programme durations of 4-54 weeks. Therefore, the total exercise volume varied widely between 960-7800 min ( Table 2) .
Risk of bias
In 10 of the studies included, the randomization sequence generation has clearly been described. 9, 28, 36, 37, 39, [43] [44] [45] [46] [47] Four of these studies 9, 36, 43, 44 failed to report the allocation concealment. Blinding of the participants and staff was not possible due to the type of intervention, resulting in a high risk of performance bias.
Most outcomes (all-cause-mortality, cardiovascular (CV) mortality, hospital admission due to heart failure) are unlikely to be influenced by a lack of blinding of the outcome assessment. In contrary, the assessment of the remaining endpoints (QoL and VO 2peak ) might be influenced.
Nineteen trials were rated as low risk of bias concerning incomplete data. In four studies, 21, 24, 28, 44 dropout rates differed between ebCR and control group. Therefore, the risk of an attrition bias is regarded as high in these trials. The HF-ACTION 37 trial had a dropout rate of 33% after 12 months for the outcome VO 2peak , whereas all randomised patients were analysed for the other outcomes. Only in seven publications, has the existence of a study protocol been reported. 37, 39, [43] [44] [45] [46] Six studies 9, 23, 26, 30, 33, 44 only included men, and therefore cannot be regarded as representative. In some studies, the quality of reporting was poor (e.g. contradiction between text and tables, confidence intervals not covering the point estimator etc.). In nine trials 22, 25, 30, 31, 34, 39, [45] [46] [47] the baseline characteristics of the intervention group were unbalanced at baseline. A summary of the risk of bias is provided in Figure 2 . The visual examination of the funnel plot revealed no visible publication bias (Figure 3 ).
Outcomes
Primary endpoint: all-cause-mortality Data for the primary endpoint -all-cause-mortalitywas provided in 19 studies.
Four studies (follow-up-periods ranging from 30 months up to 10 years) used HR for evaluating all-cause-mortality (Figure 3 ; HR 0.75, 95% CI 0.39-1.41, I
2 ¼45%). The only study with a statistically significant mortality reduction in the ebCR group was published in 1999. 21 The application of a fixed-effect model for the reported HR as a sensitivity analysis confirms these result of the primary analysis (HR 0.89, 95% CI 0.74-1.07), although the effect measure is shifted towards the null effect. The studies evaluated are dominated by the HF-ACTION trial. 37 If the HF-ACTION trial was excluded from the analysis, the result still did not reach statistical significance in favour of ebCR (HR 0.58, 95% CI 0.21-1.62, I 2 ¼0%). Eight studies reported count data for mortality after a follow-up of 12 months and seven studies after sixmonths follow-up. A significant difference was neither found after 12 months (RR 1.29, 95% CI 0.66-2.49, I
2 ¼ 0%) nor after six-months follow-up (RR 0.91, 95% CI 0.26-3.16, I 2 ¼ 0%) (Figure 4 ). The subgroup analysis (e.g. CR-mult vs CR-ex and aerobic exercise only vs aerobic plus resistance exercise) did not show any differences between the subgroups, respectively (Table 3) .
Secondary endpoints CV mortality. Twelve studies provided data for CV mortality. Three of them reported the HR for CV mortality. In two studies, 21, 40 all deaths were of CV origin, and therefore were already included into the evaluation of all-cause-mortality. The third study reporting CV mortality was the HF-ACTION trial (HR 0.92, 95% CI 0.74-1.15). 37 Four studies 23, [44] [45] [46] provide count data for CV mortality after 12 months and five studies 9, 25, 27, 34, 41 after six-months follow-up, respectively. Only a few events occurred within these studies. Results for CV mortality are summarised in Table 4 .
Composite endpoint of mortality and hospitalization. Three studies reported an HR for the composite endpoint of mortality and hospitalization, Dracup et al. 36 (HR 1.23, 95% CI 0.78-1.93), O'Connor et al. 37 (HR 0.93, 95% CI 0.85-1.02) and Jolly et al. 39 (HR 1.45, 95% CI 1.45-4.86).
Hospital admission. From an overall six studies that provided data for the outcome 'hospital admission due to any reason', Belardinelli et al. 40 is the only one that reported an HR. The observed HR is statistically significant in favour of ebCR. The CIs in this study, however, are asymmetrical around the HR. Five studies evaluating 'hospital admission after 12-months follow-up' failed to show any differences between the treatment groups 35, 39, [44] [45] [46] (RR 0.79, 95% CI 0.41-1.53; I 2 ¼ 0%) ( Figure 5 ). Ho¨llriegel et al. 44 only provided the total numbers of events and was therefore not included into the analysis.
Ten studies provided results concerning 'hospitalization due to worsening of heart failure' (Figure 6 ). (RR 0.59, 95% CI 0.12-2.91, I 2 ¼ 4%). Three studies provided data for six-months follow-up (RR 0.84, 95% CI 0.07-9.71, I
2 ¼ 0%) (Figure 6 ).
Cardiopulmonary exercise capacity. Eighteen studies reported data on cardiopulmonary exercise capacity (VO 2peak ml/min/kg). The VO 2peak was measured using cardiopulmonary exercise testing (n ¼ 13 cycle ergometer or n ¼ 5 treadmill, using different protocols) performed at baseline, after the intervention and follow-up, to document increments in exercise capacity. In one study only, 37 respiratory exchange ratio (RER)>1.0 was required as a load criterion. Ten studies 9, [21] [22] [23] 25, 26, 33, 37, 42, 45 reported mean RER values in all tests performed (n ¼ 9 mean RER > 1.0) (see overview in Supplementary Material Table SM3 ). Follow-up periods were 12-14 months (seven studies) or six months (11 studies) (Figure 7 ). Due to a considerable statistical heterogeneity effect, sizes have not been pooled (heterogeneity after 12-14 months I 2 ¼ 94.38%; heterogeneity after six months I 2 ¼ 86.66%). All but one study 45 show an increase of exercise capacity in the ebCR group. In the single study not showing this favourable effect, 45 a significant imbalance at baseline in favour of the control group was observed (MD at baseline -2.2, 95% CI -4.4-0.0).
QoL. QoL has been evaluated by a variety of instruments, but the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Minnesota Living With Heart Failure Questionnaire (MLWHF) have predominantly been used in the studies selected in CROS-HF. Therefore, data based on either KCCQ or MLWHF were used for further analysis.
Using KCCQ after six-months follow-up (two studies), 37, 41 ebCR is associated with an increased QoL as compared to the control group (MD 1.94, 95% CI 0.35-3.56, I
2 ¼ 0%); higher KCCQ scores indicate a better QoL (Figure 8 ). This improvement could not be observed after 12 months in one study. 45 MLWHF questionnaires have been used in 12 studies, whereby lower scores indicate a better QoL. Due to inconsistently reported results, the study of Bellardinelli et al. 40 was excluded. Seven trials reported QoL after a follow-up of !9 months and heterogeneity was substantial. Pooled MD was -although not statistically significant -in favour (Figure 9 ). Four trials provided data after six-months follow-up, and the results again were in favour of ebCR (MD -5.97, 95% CI -16.17-4.23, I
2 ¼ 29%) (Figure 9 ).
37,45
Discussion
In this systematic review and meta-analysis including HFrEF patients with LV-EF 40% and guidelinerecommended medical therapy, ebCR (a) did not have a significant effect on all-cause-mortality, CV mortality or hospital readmission, and (b) was associated with improved QoL and an increased exercise capacity.
The lack of any prognostic effect of ebCR in HFrEF comes as a disappointment to many exercise physiologists and rehabilitation experts, who believed that ebCR could indeed influence the underlying disease process by reducing left ventricular (LV)-dilation, improving LV-EF, and partially reversing skeletal muscle dysfunction. Neurohormonal changes like reduction of circulating catecholamines and reduced sympathetic tone, improved nitric oxide (NO) availability and endothelial function provided a pathophysiological framework to expect prognostic benefit. 9, 17, 45, 53 So why could no association between ebCR and a reduction of all-cause-mortality or cardiovascular mortality be observed? 1. Underpowered studies with small sample size: one may hypothesise that the major improvements in survival related to the introduction of standardised Renin-Angiotensin-Aldosteron-System (RAAS) blockade in combination with beta-blockers and mineralocorticoid antagonists reduced cardiac mortality to a degree, where additional effects of ebCR could only have been detected with much larger patient numbers. As exercise intervention studies do not promise the return on investment expected from drug trials, large well-powered ebCR RCTs are very rare. In fact, the Food and Drug Administration (FDA)-sponsored HF-ACTION trial is the only adequately sized mortality trial. 2. Lack of adequate patient compliance with the prescribed training programme: in HF-ACTION, 37 however, a different problem may have prevented a positive study result (i.e. a significant mortality reduction): lack of patient compliance (approximately 60%). After adjustment for highly prognostic predictors of the primary endpoint in this study, exercise training was, however, associated with modest significant reductions for both all-causemortality or hospitalization and CV mortality or heart failure hospitalization. 37 Subsequent sub-analysis confirmed a dose-response relation between training intensity (as measured by MET-h per week) and outcome improvement indicating significant reductions in adjusted HRs for all-cause/CV mortality or all-cause/cardiac hospitalization between 3-7 MET-h per week. 54 Due to the large patient number in the HF-ACTION trial (2331 patients) the lack of any prognostic benefit in the primary non-adjusted analysis dominated all subsequent meta-analyses. However, if we accept that non-pharmacological interventions should be tested according to the same rules as pharmacological therapies we must also accept the intention-to-treat principle in randomised studies. On-treatment effects are therefore merely hypothesis-generating. 3. Inherent therapeutic limitations due to an irreversibly damaged heart muscle: due to a consistently improved drug and device therapy, the well-known deleterious circulatory consequences of chronic heart failure largely could be prevented and the risk of sudden cardiac death in these patients significantly has been reduced. Therefore, the current therapeutic approaches in severe chronic heart failure may -at least in part -be exhausted.
On the upside, the current meta-analysis confirmed the positive effects of ebCR on exercise capacity and QoL. Individually adapted exercise training is able to effectively prevent muscular deconditioning with all its negative implications on activities of daily living. In this way, regular exercise training does help to stabilise physical fitness and to increase QoL in these severely ill patients, as shown in this meta-analysis. To the best of our knowledge, CROS-HF is the first meta-analysis focusing on a clearly defined cohort of HFrEF-patients with a LV-EF 40% and a minimum follow-up of six months. In addition, studies were included only if they were published in the era of modern heart failure therapy (1999 or later), and if ebCR guaranteed a minimum of supervised exercise therapy as outlined in Table 1 (CROS-HF inclusion criteria). These baseline requirements of CROS-HF resulted in a study selection different from the majority of meta-analyses published so far (see Table 2 and Supplementary Material Table SM2 ). The CROS-HFresults are in line with two recently published metaanalyses 12, 13 that also failed to show a clear effect of ebCR on mortality. In contrast to CROS-HF, these meta-analyses included a broad group of 'low' up to 'high risk' heart failure patients with an LV-EF spectrum from HFrEF over heart failure with mid-range ejection fraction (HFmrEF) 12, 13 to HFpEF.
12
With respect to the effect of ebCR on hospitalization, rates recently published reviews show variable results. Taylor et al. did not show significant effects (hospitalization due to any reason: HR 0.90, 95% CI 0.76-1.06; hospitalization due to worsening of heart failure: HR 0.98, 95% CI 0.72-1.35) 13 while the analysis of Long et al. 12 showed statistical significance in favour of ebCR (hospitalization due to any reason up to 12 months: RR 0.70, 95% CI 0.60-0.83; hospitalization due to worsening of heart failure: RR 0.59, 95% CI 0.42-0.84). The finding that CROS-HF did not show a significant reduction in hospital readmission might be explained as well by the fact that all patients had a markedly reduced LV-EF and were on a state-ofthe-art pharmaco-and device therapy. Hence, more studies evaluating larger cohorts of patients with different levels of reduced LV-EF are needed to strengthen the tendency of our results. Reduced physical performance and exercise-induced dyspnoea are key symptoms of heart failure. In HFrEF-patients the VO 2peak (ml/min/kg) is a significant prognostic predictor of allcause mortality and a 1 ml/min/kg lower VO 2peak is associated with a 16% higher all-cause-mortality. 55 A recently published study evaluated the impact of the baseline VO 2peak as well as of the increment of the exercise capacity during ebCR on the primary endpoints of death or hospitalization (n ¼ 421 HF-patients; 85 cases during 2.5 year follow-up). The results revealed an independent association between high exercise capacity at ebCR baseline and primary endpoints, during follow-up (HR 0.54, 95% CI 0.34-0.85). 56 Moreover, high exercise capacity at baseline combined with major improvement in VO 2peak during ebCR was associated
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European Journal of Preventive Cardiology 0(00) with 81% risk reduction for primary endpoints (HR 0.19, 95% CI 0.08-0.43). Importantly, a significant risk reduction was also evident in patients with low baseline values but significant increment of exercise capacity during ebCR (HR 0.41, 95% CI 0.23-0.74). 56 These results emphasise the importance of improvement in exercise capacity through ebCR. All effects for cardiopulmonary exercise capacity beside those of one study 45 are in favour of the ebCR group in the current systematic review. A previously published meta-analysis 57 also revealed a significant improvement by MD þ 2.82 ml/min/kg (95% CI 1.97-3.67) achieved through ebCR in patients with HFrEF. Higher exercise intensity was associated with greater improvements in exercise capacity. 57, 58 In addition, the effectiveness was similarly influenced by exercise frequency and volume. 58 The potential impact of the quality of exercise-based intervention being under evaluation, the adherence to exercise within and/or across trials, as well as variations in the characteristics of 'usual care' as control, has to be discussed in this context. 13 Nevertheless, an univariate meta-regression analysis of Long et al. 12 did not show any significant impact of type of exercise, exercise dose, type of rehabilitation, or exercise setting on all-cause-mortality, all hospitalizations or QoL.
Although all but one study showed improvements in exercise capacity this effect was not translated into mortality results in the CROS-HF review. This might in part be explained by the study populations included in CROS-HF-analysis, that despite our strict selection criteria showed a substantial heterogeneity, including patients with severely damaged myocardium, regarding cardiorespiratory fitness, disease history and aetiology as well as age. These factors might have influenced the individual response to exercise training. One study evaluating the impact of the response to exercise training classified those patients as non-responders who improved their VO 2peak by less than 6% during ebCR. The results showed non-responders to have a significantly higher risk for all-cause-mortality and hospitalization, as compared to responders during a follow-up of five years. Factors associated with no response to ebCR were age, baseline VO 2peak and adherence to ebCR. The inability to improve VO 2peak by ebCR was associated with a doubling of the risk for death or hospitalization. 59 The CROS-HF study revealed significant improvement of KCCQ scores after six-months follow-up. After six months and after !9 months the pooled MLWHF results were in favour of ebCR as well, but the difference was not statistically significant. The results for MLWHF in this study are comparable to those of Long et al., 12 showing significant reduction in MLWHF-scores during short-term (<12 months) and long-term (>12 months) follow-up.
Usually, all aspects of QoL are significantly impaired in patients with heart failure. 54 Improvements in health related QoL caused by interventions like ebCR or multidisciplinary transition-to-care clinic programmes were associated with a reduced hospitalization rate 60, 61 and all-cause-mortality of heart failure patients. 60 Hence, improvement of QoL is one of the most important goals in heart failure therapy, even though the mechanisms and the interrelationship between health-related QoL and prognostic outcome, are not yet fully understood. 60 
Limitations
In real life, individuals with HFpEF contribute to at least half of the patients with chronic heart failure. 60 The initial aim of CROS-HF, to evaluate the effect of ebCR on HFpEF patients as well, could not be realised, as only one pilot study fulfilled the CROS-HF selection criteria. 47 In 2017, a multicentre RCT started in a large cohort of HFpEF-patients focusing on the efficacy of 12 months supervised exercise. This trial, among others, will give more insight into this very important patient cohort. 62 The CROS-HF inclusion criteria were met by only a few studies. In addition, most of the studies included were small. Hence, the results were dominated by the large HF-ACTION trial. Moreover, integrated trials showed a considerable heterogeneity in study design, ebCR intervention and patient populations varied substantially with regard to age, disease history and aetiology as well as comorbidity and cardiorespiratory fitness. All of these characteristics do influence the individual response to exercise training making it difficult to compare study results.
Conclusion
In patients with chronic heart failure and LV-EF 40% being on current guideline-recommended pharmacological and device therapy, ebCR was associated with an increase in QoL and exercise capacity. A significant advantage regarding mortality and hospitalization, however, could not be found.
analysed the extracted data. BBW, BS BR, SG and RN were responsible for drafting the report. All authors reviewed the manuscript, gave their final approval and agreed to be accountable for all aspects of work ensuring integrity and accuracy.
Declaration of conflicting interests
